Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 128.61M P/E - EPS this Y -17.40% Ern Qtrly Grth -
Income -10.22M Forward P/E -14.30 EPS next Y -1.20% 50D Avg Chg -1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -20.00%
Dividend N/A Price/Book 11.01 EPS next 5Y - 52W High Chg -53.00%
Recommedations 2.00 Quick Ratio 5.34 Shares Outstanding 13.14M 52W Low Chg 20.00%
Insider Own 52.92% ROA -72.45% Shares Float 5.93M Beta 3.30
Inst Own 8.59% ROE -123.67% Shares Shorted/Prior 466.63K/415.62K Price 10.01
Gross Margin - Profit Margin - Avg. Volume 20,577 Target Price 38.00
Oper. Margin - Earnings Date Oct 17 Volume 19,212 Change 1.21%
About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Greenwich LifeSciences, Inc. News
09/12/24 Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders seem bullish, own 55% and have been buying more recently
08/16/24 Insider Stock Buying Reaches US$3.36m On Greenwich LifeSciences
08/01/24 Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
06/26/24 Greenwich LifeSciences Set to Join Russell 2000 Index Again
06/17/24 Insider Buying: CEO and CFO Snehal Patel Acquires Shares of Greenwich LifeSciences Inc (GLSI)
06/14/24 Greenwich LifeSciences Announces $2.5 Million Private Placement
04/10/24 Insiders are Piling into These 10 Healthcare Stocks in 2024
03/13/24 Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
03/12/24 Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
03/07/24 Greenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional Shares
02/27/24 Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
02/22/24 Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
02/14/24 Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
01/22/24 We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
12/11/23 Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently
11/21/23 Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
11/14/23 Greenwich LifeSciences Insiders Added US$653.7k Of Stock To Their Holdings
GLSI Chatroom

User Image Lets_Go_Brndn Posted - 1 day ago

$GLSI Cats out of the bag. Wasn’t going to mention this. Same thesis.

User Image taniaseb2006 Posted - 1 day ago

$GLSI how many shares every one owns.

User Image doc123266 Posted - 1 day ago

$GLSI @Rolltide2020 I prefer if the inside buy was more than a month out. That means we could be getting news on the study. There is a pause on inside buying every time they’re about to update.

User Image WallStreetBuyDip Posted - 3 days ago

I do the opposite of chasing or making a trade based on catalyst. I buy only when I get a confirmation. I wait until H% is low for a reversal trade. Will do the same for $GLSI like I did for others.

User Image Rolltide2020 Posted - 3 days ago

$GLSI Jaye just bought more. When she buys, Snehal buys (usually within a week or so).

User Image insiderbuyingselling Posted - 3 days ago

$GLSI new insider buying: 800 shares. http://insiderbuyingselling.com/?t=GLSI

User Image Rolltide2020 Posted - 6 days ago

$GLSI If we pitch a shutout in the first 14 events (all 14 events in placebo group), the price will go to (fill in the blank with comment)?

User Image LIGator Posted - 6 days ago

@bernardbaruch You seem like an intelligent person, so why are you wasting your time here with no position? I am sorry you had a bad trade with $GLSI in the past. Get over it. If you don’t believe in the company then you have two choices: walk away or short the stock (and pay me my borrowing fee). I have done extremely well without your advice.

User Image Gulfoil Posted - 6 days ago

$GLSI short squeeze day

User Image iguessitsuptome Posted - 1 week ago

$GLSI is someone from Europe and bought options? If yes, which broker? Thx in advance.

User Image Rolltide2020 Posted - 1 week ago

$GLSI Gonna f around and find out.

User Image Fargo123 Posted - 1 week ago

$GLSI

User Image KINGSTOCKERS Posted - 1 week ago

$GLSI I have not seen any stock in this sector where the CEO puts his money where his mouth is as this one, I’m rolling with him. Fear mongering only provides me with the opportunity to add at lower prices, thank you and glta

User Image Rolltide2020 Posted - 1 week ago

$GLSI Let’s all sit around the campfire and tell scary old fake White Diamond reports from April 2023 and scare the retail investors into giving away their shares. You can have my 3,500 shares at 100+ or 0 (ok maybe 70, but 100+ sounds better, don’t you think?).

User Image doc123266 Posted - 1 week ago

$GLSI @CLT123 it seems from everything CEO has said the plan is buyout. That might be wishful thinking on his part and ours but would explain not putting together sales force or distribution. Seems the only way this moves forward is with BP or else BP squashes it. Coin toss.

User Image doc123266 Posted - 1 week ago

$GLSI @CLT123 do 50% of phase 3 trials with 100% efficacy and little to no safety issues fail? Truly asking, not challenging your comments.

User Image CLT123 Posted - 1 week ago

$GLSI There’s no doubt that there are some things about this ticker that don’t line up. I don’t understand the lack of institutional investors, the WD article is concerning in some ways but overall it’s riddled with inaccuracies….written by people who don’t understand what a primary endpoint is. 12-20 year read out is ridiculous…the primary endpoint isn’t OS and can’t be in this type of BC where survival is a decade plus. However the phase III roll out has been impressive, the insider buys with the private sale of over 2M seems very bullish to me. The science makes sense too. But we all know that 50% of phase III trials fail regardless of earlier phase results. It’s a big risk so I’m planning accordingly. NIA just my thoughts.

User Image Rolltide2020 Posted - 1 week ago

$GLSI Notice the date.

User Image bernardbaruch Posted - 1 week ago

$GLSI @zerotohero1 @buylowandwait These guys at White Diamond thought in April of 2023 that the Ph 3 results may never come in. They may be full of shite, they may have an undisclosed agenda, but they sound pretty knowledgeable and experienced to me fwiw. To the best of my knowledge they have never retracted it. Due diligence experts like @Lets_Go_Brndn have gone through this report with a fine toothed comb, and have challenged the Promoter on the contents and conclusions. They were able to comfortably encourage other investors on ST to dismiss it on grounds of inaccuracy. I read it carefully & I could barely keep my lunch down. Bio is tough, that's for sure. Know what you own. Know what you know. Know what you don't know. I personally follow Buffets 2 top rules whenever possible fwiw. Plus the "no called strikes rule" Like I said, I don't understand the science side of baby bios. But clearly there are a range of opinions that all retailers are entitled to avail themselves of. NIA. https://whitediamondresearch.com/research/greenwich-lifesciences-phase-3-trial-should-be-stopped-due-to-the-manipulation-of-the-phase-2-data/

User Image Jizzle14 Posted - 1 week ago

$GLSI limits set for 13.37 dwn to 12.99

User Image buylowandwait Posted - 1 week ago

@bernardbaruch $GLSI Say what you want to say … $GLSI doesn’t sound solid at all, why? with <10M cash, the company is trying to make a dent in oncology space? Does this mean other company doesn’t know how to go through clinic trial and regulatory process to waste hundreds of millions?

User Image bernardbaruch Posted - 1 week ago

@iguessitsuptome I'm a tourist on $glsi. My agenda is unwavering on ST. I have some experience and knowledge that some find useful from time to time. I posted here again because the AH volume on Friday seemed like it might not be organic, that there may have been some choreography involved. I have no idea. My thoughts only. Take what you like, leave the rest. I don't do science DD btw. I don't have the capacity. I'm solid on C Suite behavior and on capital formation, and the active manager institutional mindset. And tape reading. I have no conviction regarding what is going to happen to this ticker. I'm taking some heat here. Yesterday a friend said that I was dumb and that he wished I didn't exist. Someone else called me arrogant. GL NIA

User Image iguessitsuptome Posted - 1 week ago

$GLSI @bernardbaruch what’s your agenda here? Are you bullish or bearish? You need attention and want to start discussions? For now I see your spreading doubt and I wonder why. Be so kind and express yourself. Thanks in advance

User Image Rolltide2020 Posted - 1 week ago

$GLSI

User Image Lets_Go_Brndn Posted - 1 week ago

$VKTX $GLSI What’s the opportunity cost of not holding these?

User Image bernardbaruch Posted - 1 week ago

@Lets_Go_Brndn B, I don't wish ill on this company. I have been consistent in sharing my analysis without making recommendations for 2.5 years now. I haven't changed at all from not too long ago when you thought that I wasn't dumb. What happened to me to make me dumb? I enjoy sharing information with retail participants that can help them "think like an institution". You know that and you know that I have done it consistently and generously. I hope that the shareholders do well on $GLSI I won't. Because it doesn't make it through my filter. So what? It's just my DD filter. It means nothing. Just another view. I can construct a positive scenario from the CEO monopolization of the stock action. He knows/knew that Wall Street phukks everyone in his position, and he knows/believes that his drug is money in the bank. So he gives the finger to the banks & their clients. Rolls into his readout with $7mm in bank & $100 mm + in his wallet It may be great. More than one way to look at it NIA

User Image Waterwing Posted - 1 week ago

$GLSI

User Image Lets_Go_Brndn Posted - 1 week ago

$GLSI He says HC Wainwrightbis bottom of the barrel. Comedy. And just plain dumb. VIVEK RAMASWAMY is headlining. https://hcwevents.com/annualconference/

User Image Zero2hero1 Posted - 1 week ago

$GLSI When do you think results will come in for phase 3 trials?

User Image Lets_Go_Brndn Posted - 1 week ago

$GLSI I wish people like this didn’t exist here. Basically asking you to ignore record setting Insider Buys atm. The data from MD Anderson as one of the BEST cancer hospitals in the world is 2nd to none- bar none. Phase 3 in US Baylor. It’s not like this is Univ of Phoenix. Europe trial sites equally impressive. Managed funds missing in Bernie’s checklist- but I bought 200k shs of $ARDX under $1 when Tutes abandoned them and I lead online retail to over vote the r/s Raab wanted. (Recently told Renz he was headed to $5-land with bundle pull out- he laughed and we have not talked since. Long ways to $10 again but will happen) Managed funds DO like liquidity and it’s not at GLSI. Until Phase 3 released. THEN IT WILL BE. Like before. At that point we will see returns that will have some questioning their own opportunity cost of their holdings. I am at peace. I know I am right. I have made hundreds of calls both US & now Europe. Might not be for everyone. That’s how legends are made.

Analyst Ratings
HC Wainwright & Co. Buy Aug 23, 24
HC Wainwright & Co. Buy May 22, 24
HC Wainwright & Co. Buy Feb 28, 24
HC Wainwright & Co. Buy Feb 20, 24
HC Wainwright & Co. Buy Apr 10, 23
HC Wainwright & Co. Buy Sep 1, 21
Aegis Capital Buy Jan 27, 21
Aegis Capital Buy Jan 26, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Patel Snehal CEO and CFO CEO and CFO Nov 10 Buy 10.1675 5,000 50,838 5,312,677 11/14/23
Patel Snehal CEO and CFO CEO and CFO Nov 03 Buy 9.11 3,500 31,885 5,307,677 11/07/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Oct 27 Buy 8.57 500 4,285 260,348 10/31/23
Patel Snehal CEO and CFO CEO and CFO Oct 26 Buy 7.97 2,500 19,925 5,304,177 10/30/23
Patel Snehal CEO and CFO CEO and CFO Oct 25 Buy 7.91 2,500 19,775 5,301,677 10/27/23
Patel Snehal CEO and CFO CEO and CFO Oct 10 Buy 9.07 1,000 9,070 5,299,177 10/12/23
Patel Snehal CEO and CFO CEO and CFO Oct 04 Buy 8.63 2,000 17,260 5,298,177 10/05/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Sep 26 Buy 8.71 600 5,226 259,848 09/28/23
Patel Snehal CEO and CFO CEO and CFO Sep 19 Buy 8.95 4,000 35,800 5,296,177 09/21/23
Patel Snehal CEO and CFO CEO and CFO Sep 11 Buy 9.48 1,000 9,480 5,292,177 09/13/23
Patel Snehal CEO and CFO CEO and CFO Aug 22 Buy 9.97 1,000 9,970 5,291,177 08/24/23
Patel Snehal CEO and CFO CEO and CFO Aug 04 Buy 10.55 2,000 21,100 5,290,177 08/08/23
Patel Snehal CEO and CFO CEO and CFO Jul 21 Buy 9.20 1,000 9,200 5,288,177 07/25/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Jul 13 Buy 9.49 250 2,372 259,248 07/17/23
Patel Snehal CEO and CFO CEO and CFO May 17 Buy 11.69 1,000 11,690 5,287,177 05/18/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Apr 28 Buy 11.22 250 2,805 258,998 05/02/23
Patel Snehal CEO and CFO CEO and CFO Apr 19 Buy 11.10 7,000 77,700 5,286,177 04/21/23
Patel Snehal CEO and CFO CEO and CFO Apr 18 Buy 11.12 2,000 22,240 5,279,177 04/20/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Apr 11 Buy 11.87 1,000 11,870 258,745 04/12/23
Patel Snehal CEO and CFO CEO and CFO Apr 11 Buy 12.42 5,000 62,100 5,271,177 04/12/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Mar 15 Buy 12.71 250 3,178 257,745 03/16/23
Patel Snehal CEO and CFO CEO and CFO Mar 10 Buy 12.12 1,000 12,120 2,737,486 03/13/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Feb 24 Buy 15.395 250 3,849 257,495 02/28/23
Patel Snehal CEO and CFO CEO and CFO Feb 17 Buy 16.53 600 9,918 2,736,486 02/22/23
Patel Snehal CEO and CFO CEO and CFO Feb 10 Buy 18.68 1,000 18,680 2,735,886 02/14/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Feb 03 Buy 20.84 250 5,210 257,245 02/07/23
Patel Snehal CEO and CFO CEO and CFO Jan 27 Buy 19.35 2,000 38,700 2,734,886 01/31/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Jan 27 Buy 19.20 250 4,800 256,995 01/30/23
Patel Snehal CEO and CFO CEO and CFO Jan 20 Buy 17.37 1,500 26,055 2,732,886 01/24/23
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Jan 13 Buy 16.50 250 4,125 256,745 01/17/23
Patel Snehal CEO and CFO CEO and CFO Jan 06 Buy 15.18 1,500 22,770 2,731,386 01/10/23
Patel Snehal CEO and CFO CEO and CFO Dec 29 Buy 15.19 4,000 60,760 2,729,886 01/03/23
Patel Snehal CEO and CFO CEO and CFO Dec 16 Buy 13.01 1,000 13,010 2,725,886 12/20/22
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Dec 16 Buy 12.94 250 3,235 256,495 12/20/22
Patel Snehal CEO and CFO CEO and CFO Dec 09 Buy 13.11 2,000 26,220 2,724,886 12/13/22
Patel Snehal CEO and CFO CEO and CFO Dec 02 Buy 13.84 1,000 13,840 2,722,886 12/06/22
Thompson Jaye VP Clinical Reg Affa.. VP Clinical Reg Affairs Dec 02 Buy 13.98 250 3,495 256,245 12/06/22
Patel Snehal CEO and CFO CEO and CFO Nov 02 Buy 8.79 2,000 17,580 2,721,886 11/04/22
Patel Snehal CEO and CFO CEO and CFO Sep 30 Buy 9.46 1,000 9,460 2,714,886 10/04/22
Patel Snehal CEO and CFO CEO and CFO Sep 29 Buy 9.23 1,000 9,230 2,713,886 10/03/22
Patel Snehal CEO and CFO CEO and CFO Jun 24 Buy 9.13 29,000 264,770 2,712,886 06/27/22
Patel Snehal CEO and CFO CEO and CFO Jun 16 Buy 7.13 8,000 57,040 2,683,886 06/17/22
Patel Snehal CEO and CFO CEO and CFO Jun 14 Buy 7.91 12,000 94,920 2,675,886 06/15/22
Patel Snehal CEO and CFO CEO and CFO Jun 10 Buy 8.33 12,000 99,960 2,663,886 06/13/22
Patel Snehal CEO and CFO CEO and CFO Jun 09 Buy 10.90 4,500 49,050 1,243,453 06/10/22
Patel Snehal CEO and CFO CEO and CFO Jun 07 Buy 8.55 6,000 51,300 1,238,953 06/08/22
Patel Snehal CEO and CFO CEO and CFO Jun 03 Buy 8.35 9,250 77,238 1,232,953 06/06/22
Patel Snehal CEO and CFO CEO and CFO Jun 02 Buy 7.38 6,774 49,992 1,223,703 06/03/22
Daugherty Frank Joseph Chief Medical Office.. Chief Medical Officer Apr 25 Buy 16.25 1,000 16,250 90,121 04/26/22
Patel Snehal CEO and CFO CEO and CFO Apr 21 Buy 16.09 6,000 96,540 1,216,929 04/22/22